DK3374359T3 - Dihydroimidazopyrazinonderivater, der er nyttige ved behandling af cancer - Google Patents
Dihydroimidazopyrazinonderivater, der er nyttige ved behandling af cancer Download PDFInfo
- Publication number
- DK3374359T3 DK3374359T3 DK16791420.9T DK16791420T DK3374359T3 DK 3374359 T3 DK3374359 T3 DK 3374359T3 DK 16791420 T DK16791420 T DK 16791420T DK 3374359 T3 DK3374359 T3 DK 3374359T3
- Authority
- DK
- Denmark
- Prior art keywords
- dihydroimidazopyrazino
- cancer treatment
- derivatives used
- derivatives
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562252726P | 2015-11-09 | 2015-11-09 | |
US201662401351P | 2016-09-29 | 2016-09-29 | |
PCT/EP2016/076932 WO2017080979A1 (en) | 2015-11-09 | 2016-11-08 | Dihydroimidazopyrazinone derivatives useful in the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3374359T3 true DK3374359T3 (da) | 2020-03-30 |
Family
ID=57241113
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16791420.9T DK3374359T3 (da) | 2015-11-09 | 2016-11-08 | Dihydroimidazopyrazinonderivater, der er nyttige ved behandling af cancer |
Country Status (35)
Country | Link |
---|---|
US (2) | US9902731B2 (da) |
EP (1) | EP3374359B1 (da) |
JP (1) | JP6877423B2 (da) |
KR (1) | KR20180074788A (da) |
CN (1) | CN108349983B (da) |
AU (1) | AU2016351813B2 (da) |
BR (1) | BR112018008397B1 (da) |
CA (1) | CA3003549A1 (da) |
CL (1) | CL2018001226A1 (da) |
CO (1) | CO2018004857A2 (da) |
CR (1) | CR20180316A (da) |
CY (1) | CY1123627T1 (da) |
DK (1) | DK3374359T3 (da) |
EA (1) | EA038028B1 (da) |
ES (1) | ES2780650T3 (da) |
HK (1) | HK1256283A1 (da) |
HR (1) | HRP20200342T1 (da) |
IL (1) | IL258953A (da) |
LT (1) | LT3374359T (da) |
ME (1) | ME03770B (da) |
MX (1) | MX2018005725A (da) |
MY (1) | MY197626A (da) |
NI (1) | NI201800058A (da) |
PE (1) | PE20181288A1 (da) |
PH (1) | PH12018500987A1 (da) |
PL (1) | PL3374359T3 (da) |
PT (1) | PT3374359T (da) |
RS (1) | RS60155B1 (da) |
SG (1) | SG11201803066VA (da) |
SI (1) | SI3374359T1 (da) |
SV (1) | SV2018005687A (da) |
TN (1) | TN2018000119A1 (da) |
TW (1) | TWI730012B (da) |
WO (1) | WO2017080979A1 (da) |
ZA (1) | ZA201803742B (da) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017068412A1 (en) | 2015-10-21 | 2017-04-27 | Otsuka Pharmaceutical Co., Ltd. | Benzolactam compounds as protein kinase inhibitors |
PT3374359T (pt) * | 2015-11-09 | 2020-03-27 | Astrazeneca Ab | Derivados de di-hidroimidazopirazinona úteis no tratamento do cancro |
GB201706327D0 (en) | 2017-04-20 | 2017-06-07 | Otsuka Pharma Co Ltd | A pharmaceutical compound |
CN110577543B (zh) * | 2018-10-10 | 2022-07-08 | 深圳市塔吉瑞生物医药有限公司 | 一种二氢咪唑并吡嗪酮化合物及包含该化合物的组合物及其用途 |
US20220213119A1 (en) | 2019-03-28 | 2022-07-07 | Jiangsu Hengrui Medicine Ca, Lid. | Thienoheterocyclic derivative, preparation method therefor and medical use thereof |
EP3978498A1 (en) | 2019-05-24 | 2022-04-06 | Jiangsu Hengrui Medicine Co., Ltd. | Substituted fused bicyclic derivative, preparation method therefor, and application thereof in medicines |
JP2023505771A (ja) * | 2019-12-05 | 2023-02-13 | アストラゼネカ・アクチエボラーグ | 式(i)の化合物の製造のための方法および中間体 |
KR20220107249A (ko) | 2019-12-06 | 2022-08-02 | 메드샤인 디스커버리 아이엔씨. | Erk 억제제로서의 티아졸로락탐 화합물 및 이의 용도 |
CN116437915A (zh) | 2020-09-29 | 2023-07-14 | 江苏恒瑞医药股份有限公司 | 一种吡咯并杂环类衍生物的晶型及其制备方法 |
AR126166A1 (es) * | 2021-06-18 | 2023-09-27 | Antengene Discovery Ltd | Combinación de un inhibidor de erk y un inhibidor de kras y usos de estos |
WO2022268065A1 (en) * | 2021-06-22 | 2022-12-29 | Fochon Biosciences, Ltd. | Compounds as erk inhibitors |
JPWO2023008462A1 (da) | 2021-07-27 | 2023-02-02 | ||
WO2023081857A1 (en) | 2021-11-04 | 2023-05-11 | Skyhawk Therapeutics, Inc. | Condensed pyridazine amine derivatives treating sca3 |
WO2023212231A1 (en) | 2022-04-27 | 2023-11-02 | Skyhawk Therapeutics, Inc. | Compositions useful for modulating splicing |
WO2023220435A1 (en) | 2022-05-12 | 2023-11-16 | Skyhawk Therapeutics, Inc. | Compositions useful for modulating splicing |
WO2024006971A2 (en) * | 2022-07-01 | 2024-01-04 | The Scripps Research Institute | Antimalarial compounds |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
WO2004041826A1 (en) * | 2002-11-06 | 2004-05-21 | Merck Sharp & Dohme Limited | Imidazopyrazinones and imidazotriazinones derivates as gaba-a receptor anxiolytic |
GB0520958D0 (en) * | 2005-10-14 | 2005-11-23 | Cyclacel Ltd | Compound |
CA2672940A1 (en) * | 2006-12-20 | 2008-07-10 | Schering Corporation | Novel jnk inhibitors |
KR101866987B1 (ko) * | 2010-12-22 | 2018-07-19 | 얀센 파마슈티카 엔.브이. | 베타-세크레타아제(BACE) 저해제로 유용한 5,6-디하이드로-이미다조[1,2-a]피라진-8-일-아민 유도체 |
EP3121178B1 (en) * | 2011-10-10 | 2018-09-19 | H. Lundbeck A/S | 6-[4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7h-imidazo[1,5-a]pyrazin-8-one as pde9 inhibitor |
JP2013166727A (ja) * | 2012-02-16 | 2013-08-29 | Dainippon Sumitomo Pharma Co Ltd | ジヒドロイミダゾピラジノン誘導体 |
CN106349217B (zh) | 2012-03-01 | 2020-08-28 | 阵列生物制药公司 | 丝氨酸/苏氨酸激酶抑制剂 |
US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
PE20160886A1 (es) | 2013-12-06 | 2016-09-14 | Genentech Inc | Inhibidores de serina/treonina cinasa |
CN105848723B (zh) | 2013-12-30 | 2019-08-02 | 基因泰克公司 | 丝氨酸/苏氨酸激酶抑制剂 |
BR112016015236B1 (pt) | 2013-12-30 | 2023-11-14 | Array Biopharma Inc. | Composto, composições farmacêuticas, usos de um composto e método in vitro de inibição da atividade da proteína quinase erk |
MY188526A (en) | 2014-04-09 | 2021-12-18 | Genentech Inc | Process for the manufacturing of medicaments |
US10412619B2 (en) * | 2014-11-14 | 2019-09-10 | Qualcomm Incorporated | Buffer status report for eDCS |
WO2016162325A1 (en) * | 2015-04-07 | 2016-10-13 | Astrazeneca Ab | Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1 (2h)-one derivatives as kinase inhibitors |
WO2016192063A1 (en) | 2015-06-03 | 2016-12-08 | Changzhou Jiekai Pharmatech Co. Ltd | Heterocyclic compounds as erk inhibitors |
CA2987963C (en) | 2015-06-03 | 2023-01-24 | Js Innopharm (Shanghai) Ltd. | Heterocyclic compounds for treating psoriasis |
PT3374359T (pt) * | 2015-11-09 | 2020-03-27 | Astrazeneca Ab | Derivados de di-hidroimidazopirazinona úteis no tratamento do cancro |
-
2016
- 2016-11-08 PT PT167914209T patent/PT3374359T/pt unknown
- 2016-11-08 JP JP2018522784A patent/JP6877423B2/ja active Active
- 2016-11-08 CA CA3003549A patent/CA3003549A1/en active Pending
- 2016-11-08 ME MEP-2020-72A patent/ME03770B/me unknown
- 2016-11-08 MY MYPI2018000675A patent/MY197626A/en unknown
- 2016-11-08 SG SG11201803066VA patent/SG11201803066VA/en unknown
- 2016-11-08 LT LTEP16791420.9T patent/LT3374359T/lt unknown
- 2016-11-08 TW TW105136236A patent/TWI730012B/zh active
- 2016-11-08 DK DK16791420.9T patent/DK3374359T3/da active
- 2016-11-08 MX MX2018005725A patent/MX2018005725A/es active IP Right Grant
- 2016-11-08 EP EP16791420.9A patent/EP3374359B1/en active Active
- 2016-11-08 AU AU2016351813A patent/AU2016351813B2/en active Active
- 2016-11-08 US US15/345,537 patent/US9902731B2/en active Active
- 2016-11-08 TN TNP/2018/000119A patent/TN2018000119A1/en unknown
- 2016-11-08 WO PCT/EP2016/076932 patent/WO2017080979A1/en active Application Filing
- 2016-11-08 CN CN201680064567.2A patent/CN108349983B/zh active Active
- 2016-11-08 PE PE2018000611A patent/PE20181288A1/es unknown
- 2016-11-08 PL PL16791420T patent/PL3374359T3/pl unknown
- 2016-11-08 CR CR20180316A patent/CR20180316A/es unknown
- 2016-11-08 EA EA201891063A patent/EA038028B1/ru unknown
- 2016-11-08 SI SI201630668T patent/SI3374359T1/sl unknown
- 2016-11-08 BR BR112018008397-6A patent/BR112018008397B1/pt active IP Right Grant
- 2016-11-08 KR KR1020187016091A patent/KR20180074788A/ko not_active Application Discontinuation
- 2016-11-08 RS RS20200392A patent/RS60155B1/sr unknown
- 2016-11-08 ES ES16791420T patent/ES2780650T3/es active Active
-
2018
- 2018-01-18 US US15/873,965 patent/US10202391B2/en active Active
- 2018-04-26 IL IL258953A patent/IL258953A/en active IP Right Grant
- 2018-05-03 NI NI201800058A patent/NI201800058A/es unknown
- 2018-05-07 PH PH12018500987A patent/PH12018500987A1/en unknown
- 2018-05-07 CL CL2018001226A patent/CL2018001226A1/es unknown
- 2018-05-07 CO CONC2018/0004857A patent/CO2018004857A2/es unknown
- 2018-05-07 SV SV2018005687A patent/SV2018005687A/es unknown
- 2018-06-06 ZA ZA2018/03742A patent/ZA201803742B/en unknown
- 2018-11-30 HK HK18115347.8A patent/HK1256283A1/zh unknown
-
2020
- 2020-02-28 HR HRP20200342TT patent/HRP20200342T1/hr unknown
- 2020-04-02 CY CY20201100314T patent/CY1123627T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3374359T3 (da) | Dihydroimidazopyrazinonderivater, der er nyttige ved behandling af cancer | |
DK3580211T3 (da) | 2-heteroaryl-3-oxo-2,3-dihydropyridazin-4-carboxamider til behandling af cancer | |
DK3288581T3 (da) | Fremgangsmåde til behandling af cancer | |
DK3468965T3 (da) | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indol-forbindelser til behandling af cancer | |
DK3478286T3 (da) | Fremgangsmåder til behandling af ovariecancer | |
DK3286311T3 (da) | Fremgangsmåde til behandling af maligniteter | |
DK3366295T3 (da) | Fremgangsmåder til behandling af filoviridae virusinfektioner | |
DK3377516T3 (da) | Sammensætning til behandling af cancer | |
DK3189082T3 (da) | Anti-pd-l1-konjugater til behandling af tumorer | |
DK3319956T3 (da) | Substituerede oxopyridinderivater | |
DK3119762T3 (da) | Benzimidazol-derivater som erbb-tyrosin-kinase-inhibitorer til behandlingen af kræft | |
DK2988743T3 (da) | Heterocykliske forbindelser, der kan anvendes til behandling af sygdom | |
DK3253762T3 (da) | 9h-pyrrolo-dipyridinderivater. | |
DK3148529T3 (da) | Forbindelser til behandling af hjernecancer | |
DK3186244T3 (da) | Dioxolananaloger af uridin til behandling af cancer | |
DK3353177T3 (da) | Tricykliske heterocykler til behandling af cancer | |
DK3393468T3 (da) | Fremgangsmåder til behandling af en immundefektsygdom | |
DK3380086T3 (da) | Cyp26-resistente rar-alpha-selektive agonister i behandling af cancer | |
DK3303616T3 (da) | Fremgangsmåder til prognose af prostatakræft | |
DK3468604T3 (da) | Farmaceutiske kombinationer til behandling af cancer | |
DK3368519T3 (da) | Hidtil ukendte, heterocykliske antiøstrogener | |
DK3662925T3 (da) | Sammensætning, der omfatter fsh, til behandling af infertilitet | |
DK3390412T3 (da) | Vandopløselige derivater af 3,5-diphenyl-diazolforbindelser | |
DK3597189T3 (da) | Krystallinske forbindelser | |
EP3244914A4 (en) | Methods for treating tauopathy |